

ITW

1 2005		<del>1</del>
TRANSMITTAL FORM  (to be used for all correspondence after initial fill Total Number of Pages in This Submission	Application Number  Filing Date  First Named Inventor  Art Unit  Examiner Name  Attorney Docket Number	PTO/SB/21 (09-04)  10/678,639  October 3, 2003  He, Biao  1642  Not yet assigned  02307O-125630US
	ENCLOSURES (Check all tha	t anniv)
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s)  Extension of Time Request Express Abandonment Request Information Disclosure Statement with PTO/SB/08A and PTO/SB/08B  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete. Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application  Power of Attorney, Revocation Change of Correspondence Add  Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Landscape Table on CD  Remarks The Commissioner is Account 20-1430.	After Allowance Communication to TC  Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please identify below):  Cited References AA-BF; Return Postcard  authorized to charge any additional fees to Deposit
	TURE OF APPLICANT, ATTOR!	NEY, OR AGENT
Signature  Printed name  Jean M. Lockyer, Ph.  Date		lo. 54,111
1/6/05	1	
<u> </u>	ERTIFICATE OF TRANSMISSIO	N/MAILING
I hereby certify that this correspondence is be envelope addressed to: Commissioner for Pa	ing deposited with the United States Postatents, P.O. Box 1450, Alexandria, VA 2231	al Service with sufficient postage as first class mail in an l3-1450 on the date shown below.

Signature	anne		
Typed or printed name	Anna C. Kundel	Date	01/06/2005

certify that this correspondence is being deposited with the United States ostal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 02307O-125630US Client Reference No.: SF 2002-071-2

imissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

On Jonsey 6, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Cull

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HE et al.

Application No.: 10/678,639

Filed: October 3, 2003

For: METHODS FOR TREATING CANCER BY INHIBITING WNT

SIGNALING

Examiner: Not yet assigned

Art Unit: 1642

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

**§1.98** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

HE et al. PATENT

Application No.: 10/678,639

Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Jean M. Lockyer, Ph.I

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

JML:ack 60389118 v1

OIPE
, C. 20
JAN 1 1 2005 8
TRADE ARIS Ostitute

ostitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known
10/678,639
October 3, 2003
He, Biao
1642
Not yet assigned
02307O-125630US

			U.S. PATENT DO	CUMENTS+	
		Document Number			
Examiner Initials*	Cite No.1	Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	6,159,462	12-12-2000	Matthews et al.	
_				·	
			<u> </u>	·	
				<del>                                     </del>	
				<del>                                     </del>	
				1	-
	-				
			·		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	For	eign Patent Docume  Number <sup>4</sup> κin	ent d Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	АВ	wo	02/088081	A2	11-07-2002	The Regents of the University of California	·	
	AC	CA	2,200,794		09-24-1998	The Governing Council of the University of Toronto		
		· -						
						•		

	 	 	 	_
Examiner Signature	Date Considered		_	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 

Applicant's unique citation designation number (optional). 

Kind Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 

Applicant is to place a check mark here if English language Translation is attached. 

60389118 v1

Substitute	for form 1449B/	PTO			Complete if Known
			01 001105	` Application Number	10/678,639
	INFORMATION DISCLOSURE			Filing Date	October 3, 2003
STAT	STATEMENT BY APPLICANT		First Named Inventor	He, Biao	
				Art Unit	1642
(	(use as many sheets as necessary)		Examiner Name	Not yet assigned	
Sheet	2	of	3	Attorney Docket Number	02307O-125630US

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	AD	APPEL, J., et al., "Elucidation of Discontinuous Linear Determinants in Peptides," <u>The Journal of Immunology</u> , February 1990, pp. 976-983, Vol. 144, USA.					
	AE	BIENZ et al., "Linking Colorectal Cnacer to Wnt Signaling," Cell, 2000, pp. 311-320, Vol. 103, Cell Press					
	AF	BROWN et al., "Wnt signaling in breast cancer: have we come full circle?" <u>Breast Cancer Res.</u> 2001, pp. 351-355, Vol. 3					
	AG	CHEN et al., "Wnt-1 Signaling Inhibits Apoptosis by Activating β-Catenin/T Cell Factor-mediated Transcription," J Cell Biol, 2001, pp. 87-96, Vol. 152, No. 1, The Rockefeller University Press.					
	АН	COX et al., "A Screen for Mutations That Suppress the Phenotype of <i>Drosophila armadillo</i> , the β-Catenin Homolog," Genetics, 2000, pp. 1725-1740, Vol. 155.					
	AI	DE LA COSTE et al., "Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas," Proc Natl Acad Sci USA, 1998, pp. 8847-8851, Vol. 95.					
	AJ	FEDI et al., "Isolation and Biochemical Characterization of the Human Dkk-1 Homologue, a Novel Inhibitor of Mammalian Wnt Signaling," J Biol Chem, 1999, pp. 19465-19472, Vol. 274, No. 27.					
	AK	FINCH, P., "Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action," <u>Proc. Natl. Acad. Sci. USA</u> , June 1997, pp. 6770-6775, Vol. 94.					
	AL.	HE et al., "Identification of c-MYC as a Target of the APC Pathway," Science, 1998, pp. 1509-1512, Vol. 281.					
	АМ	IOANNIDIS et al., "The β-catenin-TCF-1 pathway ensures CD4 <sup>+</sup> CD8 <sup>+</sup> thymocyte survival," Nat Immunol, 2001, pp.691-697, Vol. 2, No. 8.					
	AN	KATOH, et al., "WNT2B2 mRNA, Up-Regulated in Primary Gastric Cancer, Is a Positive Regulator of the WNT-β-Catenin-TCF Signaling Pathway," <u>Biochemical and Biophysical Research Communications</u> , 2001, pp. 1093-1098, Vol. 289, Elsevier Science.					
	AO	LACHER, M., et al., "Wnt-Frizzled signaling in cell proliferation and survival," Nature, 2001, 1 page, abstract only, [33]					
	AP	MATSUZAWA et al., "Siah-1, SIP, and Ebi Collaborate in a Novel Pathway for β-Catenin Degradation Linked to p53 Responses," Mol Cell, 2001, pp. 915-926, Vol. 7, Cell Press.					
	AQ	MELKONYAN et al., "SARPs: A family of secreted apoptosis-related proteins," <u>Proc Natl Acad Sci USA</u> , 1997, pp. 13636-13641, Vol. 94.					
	AR	MILLER et al., "Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca <sup>2+</sup> pathways," Oncogene, 1999, pp. 7860-7872, No. 18, Stockton Press					
	AS	MOON et al., "Structurally Related Receptors and Antagonists Compete for Secreted Wnt Ligands," <u>Cell</u> , March 1997, pp. 725-728, Vol. 88, Cell Press.					

Examiner		Date	<u> </u>
Signature	į į	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO Complete if Known Application Number 10/678,639 INFORMATION DISCLOSURE Filing Date October 3, 2003 STATEMENT BY APPLICANT First Named Inventor He, Biao Art Unit 1642 (use as many sheets as necessary) Examiner Name Not yet assigned 02307O-125630US Sheet Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AT	NUSSE et al., "Making head or tail of Dickkopf," Nature, 2001, pp. 255-256, Vol. 411.	
•	AU	ORFORD et al., "Exogenous Expression of β-Catenin Regulates Contact Inhibition, Anchorage-independent Growth, Anoikis, and Radiation-induced Cell Cycle Arrest," <u>J Cell Biol</u> , 1999, pp. 855-868, Vol. 146.	
	AV ,	POLAKIS et al., "Wnt signaling and cancer," <u>Genes Dev</u> , 2000, pp. 1837-1851, Vol. 14, Cold Spring Harbor Laboratory Press.	
	AW	RHEE, C-S., et al., "Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas," Oncogene, 2002, pp. 6598-6605, Vol. 21, Nature Publishing Group.	
-	AX	REYA et al., "Wnt Signaling Regulates B Lymphocyte Proliferation through a LEF-1 Dependent Mechanism," Immunity, 2000, pp. 15-24, Vol. 13, Cell Press.	
	AY	SATOH et al., "AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1," Nat Genet, 2000, pp. 245-250, Vol. 24.	
	ΑŻ	SHIN et al., "Intermolecular and Interdomain Interactions of a Dynamin-related GTP-binding Protein, Dnm1p/Vps1p-like Protein," <u>Journal of Biological Chemistry</u> , 1999, pp. 2780-2785 Vol. 274, USA.	
	ВА	SHOU et al., "Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA," Oncogene, 2002, pp. 878-889, Vol. 21, Nature Publishing Group.	
	BB	SUZUKI et al., "A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer," Nat Genet, 2002, pp. 141-149, Vol. 31.	
	вс	TAIPALE, J., et al., "The Hedgehog and Wnt signaling pathways in cancer," Nature, May 2001, pp. 349-354, Vol. 411, Macmillan Magazines Ltd.	
	BD	TICE, D., et al., "Syngergistic Induction of Tumor Antigens by Wnt-1 Signaling and Retinoic Acid Revealed by Gene Expression Profiling," <u>The Journal of Biological Chemistry</u> , April 2002, pp. 14329-35, Vol. 277, No. 16, USA.	
	BE	YOU et al., "Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-incuded apoptosis," <u>J Cell Biol</u> , 2002, pp. 429-440, Vol. 157, The Rockefeller University Press.	
	BF	UTHOFF et al., "Wingless-Type Frizzled Protein Receptor Signaling and Its Putative Role in Human Colon Cancer," Mol Carcinog, 2001, pp. 56-62, Vol. 31, Wiley-Liss, Inc.	

Examiner		Date	
Signature	*	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.